Review finds modest Lp(a) reductions with GLP-1 receptor agonists
Authors in Current Atherosclerosis Reports say mechanisms may include hepatic and intestinal lipoprotein changes, anti-inflammatory effects and altered adipokine signaling.
PR
By Priya Raman · Science Reporter
Oct 14 20:00 ETSource: Current atherosclerosis reports
The wire
- 01A narrative review summarizes preclinical and early clinical data suggesting modest but significant reductions in lipoprotein(a) with GLP-1 receptor agonist therapy.
- 02Lp(a) is a largely genetically set, independent cardiovascular risk factor, so any drug effect would matter for residual risk in patients already on incretin therapy.
- 03The authors state direct effects on Lp(a) remain uncertain; this is a review rather than new data, and larger studies are ongoing.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases
Current atherosclerosis reports · 2026 Oct 15 · Mikhael FG, Ayoub C, Teperikidis E et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42878985/
